Press Release

July 17, 2024 | Press Release
Truvian Health raises $74M to bring blood testing to anyone, anywhere
Read More
June 23, 2024 | Press Release
SonoThera™ to Present Late Breakthrough Data at ISTH 2024 on Development of Nonviral Hemophilia A Gene Therapy Treatment
Read More
June 20, 2024 | Press Release
ProJenX Announces Receipt of $1M Hoffman ALS Clinical Trial Award from the ALS Association
Read More
May 30, 2024 | Press Release
Aspen Neuroscience to Present at International Society for Cell & Gene Therapy (ISCT) Annual Meeting
Read More
May 15, 2024 | Press Release
Aspen Neuroscience Receives CLIN2 Grant for ANPD001 from California Institute for Regenerative Medicine (CIRM)
Read More
May 01, 2024 | Press Release
AVILAR THERAPEUTICS TO PRESENT PRECLINICAL DATA FOR MTAC (M6PR TARGETING CHIMERA) EXTRACELLULAR PROTEIN DEGRADER PLATFORM AT THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS ANNUAL MEETING
Read More
April 17, 2024 | Press Release
Aspen Neuroscience Announces First Patient Dosed in First-in-Human Phase 1/2a Clinical Trial of Autologous Neuronal Cell Replacement Therapy for Parkinson’s Disease
Read More
April 16, 2024 | Press Release
Nobias Therapeutics Joins NVIDIA Inception Program for Startups
Read More
April 08, 2024 | Press Release
Immunitas Therapeutics Presents Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting
Read More
April 08, 2024 | Press Release
Abundance of KLRB1+ (CD161) T cells in anti-PD1 non responders coupled with enhanced tumor cytotoxicity of anti-CD161 (IMT-009) with anti-PD1 makes it a rational target for combination with anti-PD-(L)1 immunotherapy
Read More